## Remarks/Arguments

Applicants gratefully acknowledge with appreciation the previous notice of allowability of claims 13, 23-30 and 32 as amended by the Examiner. Consideration of the captioned application in view of the foregoing amendment and following remarks is requested.

The claims pending and under consideration are claims 13, 23-30, and 32-35. Claim 13 has been amended to correct certain formalties in the claims and to cancel group Het<sup>1</sup> which is no longer included in presently claimed formula (I'). Claim 28 has been amended to correct the punctuation. Claim 32 has been amended to remove certain compounds not properly dependent from claim 13. New claims 33-35 have been added. Support for new claims 33-35 can be found in the specification and the original filed claims. It is respectfully submitted that no new matter has been added by virtue of this amendment.

In addition, Applicants are including herewith reference Caglioti, L., et al., J. Org., Chem, 1968, vol. 33, p 2979-81, no. 7, which the Examiner indicated was not included in the Information Disclosure Statement submitted in the present application. The Examiner is respectfully requested to consider the present claims and the reference included herewith.

Applicant respectfully submits that the application is in condition for allowance, early and favorable action is requested.

PRD 2023USPCT

This Amendment is being submitted with a Request for Continued Examination, as such no fee is believed due for this Amendment. Please charge any fees, which may be required for this submission to Johnson & Johnson Deposit Account 10-0750/PRD2023USPCT/DK.

Early favorable action on the merits is respectfully requested.

Respectfully submitted,

By /David Knasiak/
David Knasiak

Reg. No. 45,991

Johnson & Johnson One Johnson & Johnson Plaza New Brunswick, NJ 08933-7003 (732) 524-1522

Dated: August 28, 2007